[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia
Table 1
Statistical description of observation indicators of 233 patients with thrombocytopenia.
Indicators
Mean ()
Standard deviation (s)
Median (M)
Upper and lower quartiles (P25, P75)
Minimum (min)
Maximum (max)
Age (years)
61.94
7.87
63.00
57.00, 67.00
26.00
79.00
Days of treatment
5.99
4.30
5.00
3.00, 7.50
1
40
Time to increase platelets (days)
5.27
3.88
4.00
3.00, 7.00
0
21
Delay of the next chemoradiotherapy cycle (days)
4.98
8.61
2.00
0,7.00
0
91
Prolonged hospitalization due to platelet decline (days)
4.44
7.35
3.00
0,7.00
0
91
Increased hospitalization costs due to platelet decline
